Ovid Therapeutics Management
Management criteria checks 3/4
Ovid Therapeutics' CEO is Meg Alexander, appointed in Sep 2024, has a tenure of 1.75 years. total yearly compensation is $1.02M, comprised of 50.4% salary and 49.6% bonuses, including company stock and options. directly owns 0.011% of the company’s shares, worth $45.59K. The average tenure of the management team and the board of directors is 1.8 years and 3.5 years respectively.
Key information
Meg Alexander
Chief executive officer
US$1.0m
Total compensation
| CEO salary percentage | 50.38% |
| CEO tenure | 1.8yrs |
| CEO ownership | 0.01% |
| Management average tenure | 1.8yrs |
| Board average tenure | 3.5yrs |
Recent management updates
Recent updates
Long Term Epilepsy And Psychosis Pipeline Will Reshape Prospects For This Undervalued Biotech
Catalysts About Ovid Therapeutics Ovid Therapeutics is a biopharmaceutical company focused on small molecule medicines targeting neural hyperexcitability in epilepsy and neuropsychiatric conditions. What are the underlying business or industry changes driving this perspective?
Expanding Neurology Pipeline And Extended Cash Runway Will Support Powerful Long Term Upside Potential
Catalysts About Ovid Therapeutics Ovid Therapeutics is a biopharmaceutical company focused on small molecule medicines for neurological conditions linked to neural hyperexcitability. What are the underlying business or industry changes driving this perspective?Ovid Therapeutics: OV329 Promising For Neuronal Excitability In Neurological Disorders
Summary Ovid Therapeutics receives a "Hold" rating as it pivots pipeline focus after soticlestat trial failures in rare epileptic syndromes. OVID reported positive phase 1 results for OV329, a next-generation GABA-AT inhibitor targeting drug-resistant focal onset seizures, with phase 2a trials planned for 2026. Pipeline includes KCC2 activators OV350 (IV) and OV4071 (oral) for neurological and psychiatric disorders, with key data and regulatory milestones expected through 2026. Recent financing extends OVID's cash runway into 2028, but clinical and regulatory risks remain for OVID's early-stage programs. Read the full article on Seeking AlphaOvid Therapeutics: Data Readouts For Rare Epileptic Indications Late 2024
Summary Ovid Therapeutics results from the phase 3 Skyline study, using soticlestat for the treatment of patients with Dravet Syndrome, expected by or before September of 2024. The global Dravet Syndrome market is expected to reach $1 billion by 2036. Results from the phase 3 Skyway study, using soticlestat for the treatment of patients with Lennox-Gastaut Syndrome, expected by or before September 2024. The global Lennox-Gastaut Syndrome market is expected to reach $1 billion by 2030. Read the full article on Seeking AlphaWe Think Ovid Therapeutics (NASDAQ:OVID) Can Afford To Drive Business Growth
Just because a business does not make any money, does not mean that the stock will go down. For example, although...Companies Like Ovid Therapeutics (NASDAQ:OVID) Are In A Position To Invest In Growth
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...Here's Why We're Watching Ovid Therapeutics' (NASDAQ:OVID) Cash Burn Situation
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...Is Ovid Therapeutics (NASDAQ:OVID) In A Good Position To Deliver On Growth Plans?
Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...Ovid Therapeutics GAAP EPS of -$0.21 beats by $0.04
Ovid Therapeutics press release (NASDAQ:OVID): Q2 GAAP EPS of -$0.21 beats by $0.04. Cash, cash equivalents and marketable securities as of June 30, 2022 was $152.4 millionWe Think Ovid Therapeutics (NASDAQ:OVID) Needs To Drive Business Growth Carefully
Just because a business does not make any money, does not mean that the stock will go down. For example, although...Ovid Therapeutics Inc. (NASDAQ:OVID) Could Be Less Than A Year Away From Profitability
With the business potentially at an important milestone, we thought we'd take a closer look at Ovid Therapeutics Inc.'s...Analysts Just Made A Captivating Upgrade To Their Ovid Therapeutics Inc. (NASDAQ:OVID) Forecasts
Ovid Therapeutics Inc. ( NASDAQ:OVID ) shareholders will have a reason to smile today, with the analysts making...Ovid Therapeutics Inc. (NASDAQ:OVID) Just Reported Full-Year Earnings And Analysts Are Lifting Their Estimates
It's been a good week for Ovid Therapeutics Inc. ( NASDAQ:OVID ) shareholders, because the company has just released...We're Keeping An Eye On Ovid Therapeutics' (NASDAQ:OVID) Cash Burn Rate
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...Is Ovid Therapeutics Inc.'s (NASDAQ:OVID) Shareholder Ownership Skewed Towards Insiders?
If you want to know who really controls Ovid Therapeutics Inc. ( NASDAQ:OVID ), then you'll have to look at the makeup...CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Mar 31 2026 | n/a | n/a | -US$24m |
| Dec 31 2025 | US$1m | US$515k | -US$17m |
| Sep 30 2025 | n/a | n/a | -US$36m |
| Jun 30 2025 | n/a | n/a | -US$38m |
| Mar 31 2025 | n/a | n/a | -US$24m |
| Dec 31 2024 | US$2m | US$484k | -US$26m |
Compensation vs Market: Meg's total compensation ($USD1.02M) is below average for companies of similar size in the US market ($USD2.45M).
Compensation vs Earnings: Meg's compensation has been consistent with company performance over the past year.
CEO
Meg Alexander (45 yo)
Ms. Margaret Alexander, also known as Meg, is CEO of Ovid Therapeutics Inc. from January 1, 2026 and serves as its President since September 2024 and served as Chief Strategy Officer since June 2023 until...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Co-Founder & Executive Chairman | 12.2yrs | US$1.93m | 2.02% $ 8.6m | |
| CEO, President & Director | 1.8yrs | US$1.02m | 0.011% $ 45.6k | |
| Chief Business & Financial Officer and Corporate Secretary | 5yrs | US$969.16k | 0.025% $ 105.6k | |
| Chief Scientific Officer | 3yrs | no data | no data | |
| Senior Vice President of Clinical Development | 4.9yrs | no data | no data | |
| Head of Epilepsy Research | 3.3yrs | no data | no data | |
| Chief Regulatory Officer | 1.3yrs | no data | no data | |
| Senior Vice President of Corporate Affairs & Corporate Strategy | 1.3yrs | no data | no data | |
| Senior VP of Finance & Financial Planning | less than a year | no data | no data | |
| Chief Medical Officer | less than a year | no data | no data | |
| Vice President of Research and Early Development | no data | no data | no data | |
| Investor Relations Officer | no data | no data | no data |
Experienced Management: OVID's management team is not considered experienced ( 1.8 years average tenure), which suggests a new team.
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Co-Founder & Executive Chairman | 12.2yrs | US$1.93m | 2.02% $ 8.6m | |
| CEO, President & Director | less than a year | US$1.02m | 0.011% $ 45.6k | |
| Chairman of the Scientific & Clinical Advisory Board | 5.2yrs | no data | no data | |
| Independent Director | 9yrs | US$86.27k | 0% $ 0 | |
| Lead Independent Director | 10.6yrs | US$105.75k | 0.0012% $ 5.0k | |
| Member of Scientific & Clinical Advisory Board | 9.4yrs | no data | no data | |
| Member of Scientific Advisory Board | 1.9yrs | no data | no data | |
| Independent Director | 4.7yrs | US$69.94k | 0.0024% $ 10.0k | |
| Member of Scientific Advisory Board | 1.9yrs | no data | no data | |
| Member of Scientific Advisory Board | 1.9yrs | no data | no data | |
| Member of Scientific Advisory Board | 1.9yrs | no data | no data | |
| Member of Scientific Advisory Board | 2.4yrs | no data | no data |
Experienced Board: OVID's board of directors are considered experienced (3.5 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/06/20 06:51 |
| End of Day Share Price | 2026/06/18 00:00 |
| Earnings | 2026/03/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Ovid Therapeutics Inc. is covered by 16 analysts. 10 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Madison Wynne El-Saadi | B. Riley Securities, Inc. |
| Kalpit Patel | B. Riley Securities, Inc. |
| Thomas Shrader | BTIG |